First Manhattan’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

First Manhattan’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1,373,524	Closed	-$32.5M	–	1408
2019 Q3	$32.5M	Sell	1,373,524 -43,000	-3%	-$1.27M	0.18%	83
2019 Q2	$42.6M	Hold	1,416,524	–	–	0.24%	67
2019 Q1	$31.7M	Sell	1,416,524 -37,200	-3%	-$800K	0.18%	80
2018 Q4	$26.5M	Buy	1,453,724 +379,818	+35%	+$5.96M	0.16%	87
2018 Q3	$19.4M	Buy	1,073,906 +296,419	+38%	+$3.51M	0.1%	124
2018 Q2	$7.74M	Buy	777,487 +776,372	+69,630%	+$5.36M	0.04%	212
2018 Q1	$5K	Buy	+1,115	New	+$7.97K	﹤0.01%	1269

Other funds holding RARX

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Manhattan's RARX Position: Q4 2019 in Review

First Manhattan sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q4 2019, closing a stake of 1,373,524 shares — an estimated $32.5M sold.

First Manhattan first reported a position in RARX in Q1 2018 and held it in 7 quarters. The position peaked at $42.6M in Q2 2019. 146 funds tracked by Wall St. Rank hold RARX as of Q4 2019.

First Manhattan reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
First Manhattan sold 1,373,524 Ra Pharmaceuticals, Inc. Common Stock shares in Q4 2019, an estimated $32.5M.
First Manhattan first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q1 2018 and held it in 7 quarters.
First Manhattan's Ra Pharmaceuticals, Inc. Common Stock position peaked at $42.6M in Q2 2019.
146 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q4 2019.

Based on First Manhattan's 13F filing for Q4 2019, filed 13 Feb 2020.